MLICM
LAB icon

Metropolitan Life Insurance Company (MetLife)’s Standard BioTools LAB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,589
Closed -$20.1K – 2405
2022
Q1 		$20.1K Sell
5,589
-15,523
-74% -$53.6K ﹤0.01% 2094
2021
Q4 		$82.8K Buy
21,112
+3,910
+23% +$18.3K ﹤0.01% 2574
2021
Q3 		$113K Sell
17,202
-6,903
-29% -$45.4K ﹤0.01% 2461
2021
Q2 		$148K Buy
24,105
+3,182
+15% +$17K ﹤0.01% 2372
2021
Q1 		$94.6K Buy
20,923
+7,215
+53% +$39.6K ﹤0.01% 2440
2020
Q4 		$82.2K Sell
13,708
-3,724
-21% -$24.5K ﹤0.01% 2424
2020
Q3 		$130K Sell
17,432
-7,328
-30% -$50.6K ﹤0.01% 2068
2020
Q2 		$99.3K Buy
24,760
+19,229
+348% +$67K ﹤0.01% 2257
2020
Q1 		$14K Buy
+5,531
New +$18.2K ﹤0.01% 2466
2019
Q4 		– Sell
-23,495
Closed -$109K – 2550
2019
Q3 		$109K Buy
23,495
+9,263
+65% +$73K ﹤0.01% 2252
2019
Q2 		$175K Buy
14,232
+2,817
+25% +$35.9K ﹤0.01% 1977
2019
Q1 		$152K Buy
+11,415
New +$120K ﹤0.01% 2079
2018
Q2 		– Sell
-13,975
Closed -$81.6K – 2479
2018
Q1 		$81.6K Buy
13,975
+5,296
+61% +$34.8K ﹤0.01% 2379
2017
Q4 		$51K Buy
+8,679
New +$47.5K ﹤0.01% 2459
2017
Q1 		– Sell
-20,789
Closed -$151K – 2533
2016
Q4 		$151K Buy
20,789
+632
+3% +$3.97K ﹤0.01% 2493
2016
Q3 		$161K Hold
20,157
– – ﹤0.01% 2462
2016
Q2 		$182K Hold
20,157
– – ﹤0.01% 2382
2016
Q1 		$163K Hold
20,157
– – ﹤0.01% 2284
2015
Q4 		$218K Hold
20,157
– – ﹤0.01% 2205
2015
Q3 		$163K Hold
20,157
– – ﹤0.01% 2420
2015
Q2 		$488K Sell
20,157
-965
-5% -$30.5K ﹤0.01% 1761
2015
Q1 		$889K Hold
21,122
– – 0.01% 1263
2014
Q4 		$712K Hold
21,122
– – ﹤0.01% 1538
2014
Q3 		$517K Buy
21,122
+744
+4% +$20.9K ﹤0.01% 1699
2014
Q2 		$599K Hold
20,378
– – ﹤0.01% 1705
2014
Q1 		$898K Sell
20,378
-2,071
-9% -$91.1K 0.01% 1424
2013
Q4 		$860K Buy
22,449
+3,470
+18% +$102K 0.01% 1435
2013
Q3 		$416K Sell
18,979
-5,765
-23% -$113K ﹤0.01% 1876
2013
Q2 		$432K Buy
+24,744
New +$434K ﹤0.01% 1786

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LAB Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 5,589 shares — an estimated $20.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LAB in Q2 2013 and held it in 29 quarters. The position peaked at $898K in Q1 2014. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,589 Standard BioTools shares in Q2 2022, an estimated $20.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Standard BioTools in Q2 2013 and held it in 29 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Standard BioTools position peaked at $898K in Q1 2014.
  • 86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.